Skip to main content

Table 1 Patient characteristics at the first time of SBRT (n = 14)

From: Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series

Characteristics  
Age, median (range) 55.5 (40–68)
Male, no. (%) 12 (85.7)
Cause of cirrhosis, no. (%)  
 HBV 11 (78.6)
 HCV 2 (14.3)
 Alcoholic 1 (7.1)
ECOG performance status, no. (%)  
 0 9 (64.3)
 1 4 (28.6)
 2 1 (7.1)
Child–Pugh class, no. (%)  
 A 11 (78.6)
 B 2 (14.3)
 C 1 (7.1)
Previous treatment, no. (%)  
 TACE 7 (50.0)
 RFA + TACE 1 (7.1)
 TACE + Thaldo 2 (14.3)
 Segmentectomy + TACE 2 (14.3)
 Segmentectomy + TACE + RFA 1 (7.1)
 None 1 (7.1)
Max. tumor diameter, median (range) 4.45 (0.9–10.5)
Number of tumors, no. (%)  
 Solitary 4 (28.6)
 Multiple 10 (71.4)
Portal venous tumor thrombosis, no. (%) 4 (28.6)
AFP, median (range), IU/mL 59.5 (3.0–1286.0)
BCLC stage at SBRT, no. (%)  
 A 3 (21.4)
 B 6 (42.9)
 C 4 (28.6)
 D 1 (7.1)
Within Milan criteria before SBRT, no. (%) 4 (28.6)
  1. AFP, alpha-fetoprotein; BCLC, Barcelona clinic liver cancer; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, transcatheter arterial chemoembolization